IT Philadelphia Phillies managers are faced with

"IT infers 2008 world series baseball managers are eagles phillies diagnoses faced with ongoing pressures to balance energy useand reduce energy costs. Reaching this milestone is an important step towardsproviding network designers with additional tools to reduce energy consumption.""Market pressure and legislative action worldwide are demanding improvements inthe energy efficiency of networked systems," says David Law, ConsultantEngineer, 3Com and Chair for the IEEE 802.3 Working Group. IEEEP802.3az will provide end-users with the ability to reduce energy used bynetwork equipment. "This is the first project in the history of Ethernet aimed specifically atreducing energy use," says Michael Bennett, Senior Network Engineer, LawrenceBerkeley National Laboratory and Chair, IEEE P802.3az, Energy Efficient EthernetTask Force. Thestandard project is now on plan to meet its target September 2010 approval as astandard by the IEEE-SA Standards Board.

IEEE P802.3az will be known by its full name of "IEEE Standard for InformationTechnology - Telecommunications and Information Exchange Between Systems - Localand Metropolitan Area Networks - Specific Requirements Part 3: Carrier SenseMultiple Access with Collision Detection (CSMA/CD) Access Method and PhysicalLayer Specifications - Amendment: Media Access Control Parameters, PhysicalLayers and Management Parameters for Energy-Efficient Ethernet." When completed, the project will extend the existing IEEE Std 802.3 Ethernetstandard to facilitate transition to and from lower power consumption inresponse to changes in network demand for twisted-pair and backplane PHYs autographed baseball . World's First Standard for Ethernet Specifically Directed at Power Reduction PISCATAWAY, N.J.--(Business Wire)--The development of Ethernet communication standards reached a major milestonethis week when the IEEE 802.3 Working Group approved forwarding the draft of theIEEE P802.3az Energy-Efficient Ethernet standard to Working Group ballot pat burrell . INVESTOR CONTACTS: ElanWyethChris Burns Justin VictoriaPh: 800-252-3526 Ph: 973-660-5340David MarshallPh: 353-1-709-4444MEDIA CONTACTS:ElanWyethMary Stutts Douglas Petkus Ph: 650-794-4403 or 650-823-5255 Ph: 973-660-5218 Miriam Mason Gwendolyn FisherPh: 650-238-7113 or 650-877-7616 Ph: 484-865-5160 Elan Corporation PLC Copyright Business Wire 2009 philadelphia phillies . It is a leader in the discovery,development, manufacturing and marketing of pharmaceuticals, vaccines,biotechnology products, nutritionals and non-prescription medicines that improvethe quality of life for people worldwide philadelphiaphillies . The Company`s major divisions includeWyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

About ElanElan Corporation, plc is a neuroscience-based biotechnology company committed tomaking a difference in the lives of patients and their families by dedicatingitself to bringing innovations in science to fill significant unmet medicalneeds that continue to exist around the world baseball tickets . Elan shares trade on the NewYork, London and Dublin Stock Exchanges philies cap . For additional information about thecompany, please visit http:// About WyethWyeth (NYSE:WYE) is one of the world`s largest research-driven pharmaceuticaland health care products companies philies hat . The AIP is also currentlyconducting clinical trial enrollment throughout Europe and the United States forits lead investigative compound bapineuzumab eagles phillies . An extensive global Phase 3 clinical program was initiated in December 2007 forbapineuzumab as a potential treatment for patients with mild to moderateAlzheimer`s disease. To learn more about this trial and potential enrollment,patients or caregivers should contact clinical sites directly. Participatingclinical sites in North America can be found by visiting orcalling 1 (888) 818-MEMORY.

For study information outside North America, visit cole hamels bio . Study site details also can be found on pat burrell . In addition, the AIP is continuing to conduct safetytrials with bapineuzumab subcutaneous and ACC-001 philadelphia phillies . TheAIP is committed to researching the burden of care and cost of AD as well asdeveloping tools that help advance these efforts . As Alzheimer`s diseaseprogresses, individuals may also experience changes in personality and behavior,such as anxiety, suspiciousness or agitation, as well as delusions orhallucinations. About the Elan and Wyeth CollaborationThe Alzheimer's Immunotherapy Program (AIP) is a collaboration between Elan andWyeth to research, develop, and commercialize immunotherapeutic approaches thatmay be used to treat and possibly prevent the onset of Alzheimer`s disease.